Aminotransferase Levels and Silymarin in de novo Tacrine-Treated Patients with Alzheimer’s Disease
| Autor: | S. Schuck, S. Lebreton, J.M. Gandon, A. Strenge-Hesse, P. Brissot, Hervé Allain, W. Braun |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Cognitive Neuroscience medicine.medical_treatment Silibinin Neuropsychological Tests Pharmacology Protective Agents Transaminase chemistry.chemical_compound Cognition Double-Blind Method Alzheimer Disease Internal medicine medicine Humans Hepatoprotective Agent Transaminases Aged Cholinesterase Chemotherapy biology business.industry medicine.disease Psychiatry and Mental health Endocrinology chemistry Tacrine Toxicity biology.protein Cholinesterase Inhibitors Chemical and Drug Induced Liver Injury Geriatrics and Gerontology Alzheimer's disease Cognition Disorders business Silymarin medicine.drug |
| Zdroj: | Dementia and Geriatric Cognitive Disorders. 10:181-185 |
| ISSN: | 1421-9824 1420-8008 |
| DOI: | 10.1159/000017117 |
| Popis: | Background: Silymarin is a well-known hepatoprotective agent. Tacrine, the first drug marketed for Alzheimer’s disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients. This 12-week randomised, double-blind, placebo-controlled study was undertaken to evaluate the ability of silymarin to antagonise or prevent the hepatotoxic effects of tacrine and to analyse its action on tacrine efficacy and tolerability. Methods: Outpatients suffering from mild-to-moderate dementia of the Alzheimer type were randomly assigned to two treatment groups: tacrine + silymarin and tacrine + placebo. The study was double-blind for silymarin and open for tacrine and was conducted in 22 French neurology and geriatric centres. Silymarin (420 mg/day) was given first (1 week) and tacrine was added at 40 mg/day for 6 weeks, then increased to 80 mg/day (6 weeks). Serum ALAT was the main evaluation criterion (> upper limit of normal, ULN). Serum ASAT as well as adverse side effects and cognitive performance assessed by MMSE and the Syndrome Kurtz test (SKT) were secondary evaluation criteria. Null hypotheses were evaluated with Fisher’s exact test. Findings: 222 patients were recruited and received silymarin and tacrine (110 patients) or placebo and tacrine (112 patients). 28 patients dropped out; 217 were included in the intent-to-treat analysis. No statistical difference was observed between the two groups for serum ALAT (p = 0.39). Fewer patients had ALAT levels >5 ULN in the silymarin group (–33.3%). Side effects and notably gastrointestinal disorders were much less frequent in the silymarin group. Cognitive performance remained unchanged in both groups. Interpretation: Silymarin does not prevent tacrine-induced ALAT elevation but does reduce the rate of gastrointestinal and cholinergic side effects without any impact on cognitive status. As a consequence, silymarin (420 mg/day) could be co-administered with tacrine to improve tolerability in the initial phases of AD treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|